Search the Newsreel

Supernus Pharmaceuticals, Inc. (SUPN) Indivior Pharmaceuticals, Inc., - M&A Call - Slideshow

This article provides access to a slide deck published by Supernus Pharmaceuticals, Inc. concerning an M&A call related to Indivior Pharmaceuticals, Inc. The content is presented by SA Transcripts, a team responsible for developing and publishing earnings call transcripts on Seeking Alpha.

Agenus Files for Resale of Up to 78 Million Shares

Agenus Inc. has filed to resell up to 78 million shares. This announcement follows recent positive news for the company, including strong second-quarter earnings, a price target adjustment from B. Riley, and significant funding from RA Capital Management, L.P. The biotech company is focused …

Agenus: Q2 Earnings Snapshot

Agenus Inc. (AGEN) reported a second-quarter loss of $550,000, translating to 1 cent per share. The biotechnology company achieved $34.5 million in revenue for the period. Agenus shares have more than doubled since the start of the year, with a 46% increase in the …

NuScale Power (SMR) Expands Its Nuclear Fuel Plans With New Reactor Partnership

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. NuScale Power (NYSE: SMR) announced a new collaboration with Curio and Framatome to develop integrated nuclear fuel solutions for advanced reactors. The partnership focuses on technical assessment, …

AGENUS INC (AGEN) awards 100,000 stock options to its CMO

AGENUS INC (AGEN) has granted 100,000 stock options to its Chief Medical Officer, Steven J. O'Day, on August 5, 2026. These options have an exercise price of $7.7800 per share and will expire on August 5, 2036. The options vest over three years, with …

Agenus Inc. (AGEN) awards 50,000 stock options to director Wright

Agenus Inc. has awarded 50,000 stock options to director Timothy Wright under its 2019 Amended and Restated Equity Incentive Plan. The options have an exercise price of $7.78 per share, expire on August 5, 2036, and will vest over three years. This grant aims …

SUPN vs. TEVA: Which Stock Should Value Investors Buy Now?

Investors with an interest in Medical - Generic Drugs stocks have likely encountered both Supernus Pharmaceuticals (SUPN) and Teva Pharmaceutical Industries Ltd. (TEVA). But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find …

ALTIN YUNUS ÇEŞME TURİSTİK TESİSLER A.Ş.(AYCES) Katılım Finansı İlkeleri Bilgi Formu 6 Ağustos 2026

Janus International Group, Inc. $JBI Shares Acquired by Dimensional Fund Advisors LP

Dimensional Fund Advisors LP increased its stake in Janus International Group, Inc. by 12.7% in the first quarter, acquiring 474,205 additional shares, bringing their total ownership to 3.03%. Despite this institutional investment, analyst sentiment for JBI is largely cautious, with an average "Hold" rating …

Agenus (AGEN) Earnings Date and Reports 2026

Agenus earnings missed by $0.02, revenue was in line with estimates

NuScale Power (SMR) Stock Faces Contract Pressure Despite Its $1.9b Cash Buffer

Astrindo Nusantara (BIPI) Memacu Bisnis di Paruh Kedua

This Stock Could Be Your Ticket to Becoming a Millionaire

Aggressive growth investors understand that to substantially increase their portfolio's growth prospects, they typically must accept greater risk and volatility. As the saying goes, there's no such thing as a free lunch. The trick is to find the best balance between upside potential and …

NuScale's Revenue Plunged 99% Last Quarter, But the Stock Has Gained 1% So Far. Here's What Investors Need to Know.

Yesterday, Aug. 5, NuScale Power (NYSE:SMR) reported what, on the surface, looked like a brutal quarter. Its net loss came in at about $50 million, while its second-quarter revenue sank 99%, from roughly $8 million reported a year ago to about $75,000. It's the …

SMR Q2 Earnings Call Focuses on TVA and Deployment Readiness

NuScale Power Corporation SMR used its second-quarter 2026 earnings call to emphasize commercial readiness rather than current revenues. Management said regulatory approvals, conventional fuel, mature engineering and supplier preparation position the company to move after customers sign definitive agreements. The company reported a loss …

Is Agenus Inc (AGEN) Overvalued After Q2 Earnings Beat? Q2 EPS: $0.06, Revenue: $34.5M; GF Score: 40/100

Curio, NuScale Power, and Framatome Sign Strategic MOU to Advance the Future Nuclear Fuel Cycle

Fuel recycling, fuel manufacturing, and advanced nuclear reactor leaders join forces to evaluate next-generation nuclear fuel cycle solutions WASHINGTON, August 06, 2026--(BUSINESS WIRE)--Curio®, a leader in advanced nuclear recycling technologies, today announced the signing of a Memorandum of Understanding (MOU) with NuScale Power Corporation …

Agenus Inc (AGEN) News, Articles, Events & Latest Updates

This article provides recent news and updates for Agenus Inc. (AGEN), an immuno-oncology company. Key highlights include the company's Q2 2026 earnings report, advancements in its Phase 3 ROBBIN trial, presentations at ESMO 2026, and securing $340 million in financing to support its strategic …

Patronus Resources (ASX:PTN) Gains as Zenith Bid Adds Scale to Gold Strategy

supernus pharmaceuticals, inc. Positive Earnings Pre-Announcements

Supernus Pharmaceuticals, Inc. announced positive earnings pre-announcements, updating its fiscal year 2026 revenue range from $840-$870 Million to $860-$890 Million. The company has been active in mergers and acquisitions, including a proposed merger with Indivior and an acquisition of Sage Therapeutics, and has seen …

Unusual Machines (UMAC) Earnings Date and Reports 2026

Supernus Pharmaceuticals (SUPN) Jumps On Merger Terms, Is The Stock Still Cheap?

Agenus Inc. (NASDAQ: AGEN) posts Q2 2026 revenue, secures $85M placement

Agenus advances Phase 3 ROBBIN trial of botensilimab-balstilimab in neoadjuvant MSS colon cancer

Agenus is moving forward with its Phase 3 ROBBIN trial for botensilimab and balstilimab in high-risk Stage II-III MSS colon cancer, with the first patient dosing expected in Q1 2027. This advancement follows positive results from earlier trials, NEST and UNICORN, which demonstrated significant …

NuScale Power Corporation (SMR) Reports Q2 Loss, Lags Revenue Estimates

NuScale Power Corporation (SMR) came out with a quarterly loss of $0.13 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.13 per share a year ago. These figures are adjusted for non-recurring items. A quarter ago, it …

Supernus Pharmaceuticals Inc (SUPN) (Q2 2026) Earnings Call Highlights: Strong Revenue Growth ...

Supernus Pharmaceuticals Inc (SUPN) reported strong revenue growth in Q2 2026, driven by key product sales and advancements in its late-stage pipeline. Despite competitive pressures and increased R&D expenses, the company reaffirmed its full-year financial guidance, projecting net revenue between $640 million and $660 …

NuScale Power (NYSE: SMR) Q2 2026 results show loss and $1.9B liquidity

NuScale Power (NYSE: SMR) reported a net loss of $47.5 million, or $0.13 per share, for Q2 2026, compared to a $17.6 million loss in the prior year, primarily due to higher R&D and G&A expenses. Revenue decreased significantly to $75 thousand from $8.0 …

Janus Living, Inc. 2Q 2026: Revenue $216.5M, EPS $0.05— 10-Q Summary

IPO and follow-on fuel Janus Living (NASDAQ: JAN) as it posts $14,858 Q2 profit

NuScale Power Reports Second Quarter 2026 Results

Second Quarter 2026 Highlights NuScale's exclusive global strategic partner, ENTRA1 Energy ("ENTRA1"), continues to advance discussions with the Tennessee Valley Authority ("TVA") toward a definitive power purchase agreement for potentially the largest nuclear power deployment program in U.S. history NuScale is working with S.N. …

JAN Stock Price and Chart — NYSE:JAN

This article provides an overview of Janus Living, Inc. (NYSE: JAN), a senior housing real estate investment trust. It details key financial statistics, including market capitalization, dividend yield, and recent earnings, highlighting significant revenue growth and raised guidance. The article also covers analyst ratings, …

Cooke & Bieler (JBI) discloses 5.10M Janus International shares in 13G/A

Cooke & Bieler L.P. filed an amended Schedule 13G/A, disclosing a beneficial ownership of 5,099,757 shares of Janus International Group, Inc. common stock, which represents 3.7% of the class. The firm reports shared voting power over 4,863,180 shares and shared dispositive power over all …

Press Release: Janus Living Reports Second Quarter 2026 Results and Increases Full Year 2026 Guidance

Janus Living announced its second quarter 2026 financial results, reporting strong performance that led to an increase in its full-year 2026 guidance. The company's positive financial trajectory indicates a successful first half of the year and confidence in continued growth. This updated outlook suggests …

Janus Living (NASDAQ: JAN) lifts 2026 guidance after Q2 revenue jumps 45%

Janus Living (NASDAQ: JAN) reported strong Q2 2026 results, with consolidated revenues up 45% year-over-year to $216 million and diluted EPS reaching $0.05. The company also announced significant portfolio expansion through acquisitions totaling $1.8 billion year-to-date and raised its full-year 2026 guidance for diluted …

NuScale Stock Decays After Q2 Revenues Miss Estimates - NuScale Power (NYSE:SMR)